Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)

NCT06486441 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

640

Enrollment

INDUSTRY

Sponsor class

Conditions

Endometrial Cancer

Interventions

DRUG: Sacituzumab govitecan-hziy
DRUG: Doxorubicin
DRUG: Paclitaxel

Sponsor

Gilead Sciences

Collaborators

[object Object]
[object Object]
[object Object]